An advanced stochastic model for mucociliary particle clearance in cystic fibrosis lungs

Journal of Thoracic Disease

Volumn 4, Issue 1, 2012, Pages 48-57

  Sturm, Robert ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

24 h retention; Clearance model; Mucociliary clearance; Stochastic lung structure

Indexed keywords

EID: 84861972279     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2011.09.09     Document Type: Article

References (34)

1. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002;54:1359-71.
2. Cutting GR. Genotype defect: Its effect on cellular function and phenotypic expression. Sem Respir Crit Care Med 1994;15:356-63.
3. Welsh MJ, Tsui TF, Boat LC, Beaudet AL. Cystic Fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. Cystic Fibrosis., Vol. 7. New York: McGraw-Hill 1995. p .3799-876.
4. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
5. Poschet JF, Boucher JC, Tatterson L, Skidmore J, Van Dyke RW, Deretic V. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc Natl Acad Sci U S A 2001;98:13972-7.
6. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A 1995;92:3019-23.
7. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36.
8. Widdicombe JH. Altered NaCl concentration of airway surface liquid in cystic fibrosis. Pflugers Arch 2001;443 Suppl 1:S8-10.
9. Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999;103:1113-7.
10. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15.
11. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25.
12. Wanner A, Salathé M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996;154:1868-902.
13. Lippmann M, Yeates DB, Albert RE. Deposition, retention, and clearance of inhaled particles Br J Ind Med 1980;37:337-62.
14. Albert RE, Lippmann M, Briscoe W. The characteristics of bronchial clearance in humans and the effects of cigarette smoking. Arch Environ Health 1969;18:738-55.
15. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001;118:223-36.
16. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-7.
17. Lee PS, Gerrity TR, Hass FJ, Lourenco RV. A model for tracheobronchial clearance of inhaled particles in man and a comparison with data. IEEE Trans Biomed Eng 1979;26:624-30.
18. Cuddihy RG, Yeh HC. Respiratory tract clearance of particles and substances dissociated from particles. In: Mohr U, editor. Inhalation toxicology: The design and interpretation of inhalation studies and their use in risk assessment. Berlin: Springer;1988.p.169-93.
19. Asgharian B, Hofmann W, Miller FJ. Mucociliary clearance of insoluble particles from the tracheobronchial airways of the human lung. J Aerosol Sci 2001;32:817-32.
20. Sturm R, Hofmann W. Stochastic modeling predictions for the clearance of insoluble particles from the tracheobronchial tree of the human lung. Bull Math Biol 2007;69:395-415.
21. Hofmann W, Sturm R. Stochastic model of particle clearance in human bronchial airways. J Aerosol Med 2004;17:73-89.
22. International Commission on Radiological Protection (ICRP). Human respiratory tract model for radiological protection. Publication 66. Oxford: Pergamon Press;1994.478 p.
23. Sturm R, Hofmann W. Mechanistic interpretation of the slow bronchial clearance phase. Radiat Prot Dosimetry 2003;105:101-4.
24. Yeh HC, Schum GM, Duggan MT. Anatomic models of the tracheobronchial and pulmonary regions of the rat. Anat Rec 1979;195:483-92.
25. Koblinger L, Hofmann W. Monte Carlo modeling of aerosol deposition in human lungs. Part I: Simulation of particle transport in a stochastic lung structure. J Aerosol Sci 1990; 21:661-74.
26. Lindström M, Camner P, Falk R, Hjelte L, Philipson K, Svartengren M. Long-term clearance from small airways in patients with cystic fibrosis. Eur Respir J 2005;25:317-23.
27. King M, Chang HK, Weber ME. Resistance of mucus-lined tubes to steady and oscillatory airflow. J Appl Physiol 1982;52:1172-6.
28. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med 2002;166:1240-7.
29. Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback EG. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993;103:1390-6.
30. Oberdörster G. Lung particle overload: implications for occupational exposures to particles Regul Toxicol Pharmacol 1995;21:123-35.
31. Levy LS. Review: The 'particle overload' phenomenon and human risk assessment. Indoor Built Env 1995;4:254-62.
32. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Ped Resp Rev 2007;8:24-9.
33. Morrow PE. Alveolar clearance of aerosols. Arch Int Med 1973;131:101-8.
34. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thoracic Soc 2004;1:315-20.